Precision Medicine Conference 2013
Industrial methodology for process verification in research (Improver) was designed as a methodology to validate industrial research processes related to systems biology by decomposing an industrial research workflow into individual components, termed building blocks that can be independently verified. The first Challenge (Diagnostic Signature) was designed to determine to what extent transcriptomic data can be used for phenotype prediction and to identify best-performing computational methods. The second Challenge (Species Translation) was designed to address the extent to which biological effects of stimulus-induced perturbations in one species translate to those in another species. In the third Challenge we will provide the community with network models of molecular events contributing to the onset of early Chronic Obstructive Pulmonary Disease (COPD). These models of key biological processes include access to underlying scientific literature citations that have been expertly curated to provide mechanistic substantiation for each molecular relationship present in the network model. The scientific community will be encouraged in the review of the relationships between molecular entities and to make improvements on the represented biology covering fundamental processes involved in respiratory disease. Our fourth Challenge (Grand Challenge) aims to discover molecular biomarkers for early stage COPD leveraging the learning from the previous Challenges. Presented by E Bilal.
PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization.
Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.